Bortezomib for the treatment of multiple myeloma

Scott, Kathleen M.; Hayden, Patrick; Will, Andrea; Wheatley, Keith; Coyne, Imelda

doi:10.1002/14651858.cd010816.pub2

Cited by 99 publications

(97 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For ASCT recipients there was no significant difference between the two cohorts with respect to OS, although patients in the post‐cohort had a significantly longer PFS. This is consistent with clinical trial data on the effects of bortezomib in ASCT and both the 5‐year OS and median PFS were similar to that reported in recent trials and North American hospitals …”

Section: Discussionsupporting

confidence: 91%

“…Because these sub‐groups differ substantially with respect to treatment and/or survival, they are analysed as distinct groups in clinical trials . Current data suggest these sub‐groups may respond differently to changes in NA . However to date, only limited data are available on the impact that changes in the therapeutic use of NA have had on ‘real life’ clinical outcomes in these quite distinct patient sub‐groups …”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre

Hock

Mulholland

Ganly

et al. 2019

Internal Medicine Journal

View full text Add to dashboard Cite

Background The impact of changes in novel agent (NA) usage on the survival of multiple myeloma (MM) patients in real‐world hospital settings is unclear. In New Zealand (NZ) in 2011, frontline bortezomib became available and thalidomide availability was expanded. Aim This retrospective study analyses the impact these change had on the survival of MM patients treated at a NZ hospital. Methods Clinical and overall survival (OS) data were collected on MM patients who were treated at Christchurch Hospital during 2000–2009 (pre‐cohort, n = 337) and 2011–2017 (post‐cohort, n = 343). Outcomes were compared using pre‐cohort data truncated at 2011. Results Patients in the post‐cohort had significant increases (P < 0.001) in not only NA usage (85 vs 55%) and OS (median = 56 vs 44 months) but also the proportion (74 vs 49%) of young patients (age < 70) who received an autologous stem cell transplant (ASCT). Separate analysis of older patients demonstrated that those in the post‐cohort had significantly longer OS (median OS 28 vs 17, P < 0.001) although 5‐year relative survival remained less than 50%. Separate analysis of young patients demonstrated that those in the post‐cohort had significantly increased initial OS with the survival curves converging at 5 years. Although ASCT‐treated patients had similar OS in each cohort, their progression‐free survival (PFS) was significantly increased in the post‐cohort (median 40 vs 20 months, P < 0.0001). Conclusion In the setting of a NZ hospital the increased availability of NA was associated with a significant improvement in both the OS of older patients and the PFS of ASCT patients.

show abstract

Section: Discussionsupporting

confidence: 91%

Section: Introductionmentioning

confidence: 99%

Impact of increased access to novel agents on the survival of multiple myeloma patients treated at a single New Zealand centre

Hock

Mulholland

Ganly

et al. 2019

Internal Medicine Journal

View full text Add to dashboard Cite

show abstract

“…Moreover, it should be pointed out the relevance of bortezomib (PS-341), a proteasome inhibitor, in the treatment of MM and mantle cell lymphoma patients. Relapse/refractory but also newly diagnosed cases benefit of bortezomib either as single agent or combined with other therapies [164, 165]. Indeed, bortezomib has been reported to repress HIF-1 (and not HIF-2)-dependent transcriptional activity by reinforcing FIH-mediated inhibition of p300 recruitment [166].…”

Section: Hypoxia And/or Hifs As Targets To Treat Hmsmentioning

confidence: 99%

The hypoxia signalling pathway in haematological malignancies

2017

View full text Add to dashboard Cite

Haematological malignancies are tumours that affect the haematopoietic and the lymphatic systems. Despite the huge efforts to eradicate these tumours, the percentage of patients suffering resistance to therapies and relapse still remains significant. The tumour environment favours drug resistance of cancer cells, and particularly of cancer stem/initiating cells. Hypoxia promotes aggressiveness, metastatic spread and relapse in most of the solid tumours. Furthermore, hypoxia is associated with worse prognosis and resistance to conventional treatments through activation of the hypoxia-inducible factors. Haematological malignancies are not considered solid tumours, and therefore, the role of hypoxia in these diseases was initially presumed to be inconsequential. However, hypoxia is a hallmark of the haematopoietic niche. Here, we will review the current understanding of the role of both hypoxia and hypoxia-inducible factors in different haematological tumours.

show abstract

“…The most common side effects of bortezomib are gastrointestinal symptoms, thrombocytopenia, neutropenia, fatigue and peripheral neuropathy [3]. Adverse cutaneous reactions during the therapy are …”

Section: Listy Do Redakcjimentioning

confidence: 99%